News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 American Society of Clinical Oncology Annual Meeting


6/3/2013 10:15:51 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NATICK, Mass., June 2, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, today announced the presentation of clinical data from an ongoing phase 1 clinical trial of its lead oral SINE selinexor (KPT-330) in patients with advanced solid tumors at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL. The data suggest that selinexor is generally safe and well tolerated as a single agent and exhibits the first signs of clinical efficacy in heavily pre-treated patients with advanced solid tumors even at low dose levels.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES